CA1341576C - Diagnosis of retinoblastoma - Google Patents
Diagnosis of retinoblastomaInfo
- Publication number
- CA1341576C CA1341576C CA000544093A CA1341576A CA1341576C CA 1341576 C CA1341576 C CA 1341576C CA 000544093 A CA000544093 A CA 000544093A CA 1341576 A CA1341576 A CA 1341576A CA 1341576 C CA1341576 C CA 1341576C
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- retinoblastoma
- polypeptide
- gene
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000000582 Retinoblastoma Diseases 0.000 title claims abstract description 69
- 238000003745 diagnosis Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 77
- 108700028369 Alleles Proteins 0.000 claims abstract description 52
- 230000002950 deficient Effects 0.000 claims abstract description 21
- 108700025701 Retinoblastoma Genes Proteins 0.000 claims description 99
- 239000012634 fragment Substances 0.000 claims description 83
- 239000000523 sample Substances 0.000 claims description 75
- 150000007523 nucleic acids Chemical class 0.000 claims description 66
- 108020004414 DNA Proteins 0.000 claims description 62
- 108020004707 nucleic acids Proteins 0.000 claims description 56
- 102000039446 nucleic acids Human genes 0.000 claims description 56
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 56
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 56
- 229920001184 polypeptide Polymers 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- 206010028980 Neoplasm Diseases 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 230000037430 deletion Effects 0.000 claims description 35
- 238000012217 deletion Methods 0.000 claims description 35
- 230000035772 mutation Effects 0.000 claims description 26
- 108050002653 Retinoblastoma protein Proteins 0.000 claims description 24
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 17
- 230000001613 neoplastic effect Effects 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 17
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 16
- 239000002853 nucleic acid probe Substances 0.000 claims description 16
- 238000009396 hybridization Methods 0.000 claims description 14
- 239000002299 complementary DNA Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 230000007547 defect Effects 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 239000013611 chromosomal DNA Substances 0.000 claims description 6
- 230000000704 physical effect Effects 0.000 claims description 6
- 102000053602 DNA Human genes 0.000 claims description 4
- 206010071602 Genetic polymorphism Diseases 0.000 claims description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 4
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 230000016178 immune complex formation Effects 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 2
- 238000012216 screening Methods 0.000 abstract description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 201000008968 osteosarcoma Diseases 0.000 description 9
- 230000002207 retinal effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 7
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 7
- 108020004518 RNA Probes Proteins 0.000 description 6
- 239000003391 RNA probe Substances 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108091006629 SLC13A2 Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000009163 protein therapy Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 101500006448 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) Endonuclease PI-MboI Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000016096 Hereditary retinoblastoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010015831 extraocular retinoblastoma Diseases 0.000 description 1
- 201000008949 familial retinoblastoma Diseases 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000005861 gene abnormality Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4736—Retinoblastoma protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89516386A | 1986-08-11 | 1986-08-11 | |
| US895,163 | 1986-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1341576C true CA1341576C (en) | 2008-07-08 |
Family
ID=25404097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000544093A Expired - Fee Related CA1341576C (en) | 1986-08-11 | 1987-08-10 | Diagnosis of retinoblastoma |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP0259031B1 (de) |
| JP (4) | JP2779161B2 (de) |
| AT (2) | ATE230442T1 (de) |
| AU (1) | AU600293B2 (de) |
| CA (1) | CA1341576C (de) |
| DE (2) | DE3752360T2 (de) |
| ES (2) | ES2063739T3 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8712646D0 (en) * | 1987-05-29 | 1987-07-01 | Clayton Found Res | Structural evidence |
| US5851991A (en) * | 1987-08-31 | 1998-12-22 | The Regents Of The University Of California | Therapeutic use of the retinoblastoma susceptibility gene product |
| US7105156B1 (en) | 1987-09-17 | 2006-09-12 | The Regents Of The University Of California | Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells |
| DE68928728T2 (de) * | 1988-01-21 | 1998-12-10 | Massachusetts Eye & Ear Infirmary, Boston, Mass. | Diagnose von retinoblastoma |
| ATE108491T1 (de) * | 1988-03-18 | 1994-07-15 | Baylor College Medicine | Mutationsnachweis durch kompetitiven oligonukleotid-priming. |
| JP2706667B2 (ja) * | 1988-10-06 | 1998-01-28 | 株式会社セラリカ野田 | 抗 体 |
| DE69032864T3 (de) * | 1989-03-29 | 2013-01-31 | The Johns Hopkins University | Nachweis des Ausfalls des Wildtyps des p53-Gens |
| CA2014473A1 (en) * | 1989-04-14 | 1990-10-14 | Hong-Ji Xu | Purified, highly specific antibodies against gene products including retinoblastoma and method |
| US5262321A (en) * | 1991-05-31 | 1993-11-16 | Dana-Farber Cancer Institute | DNA encoding p107 tumor suppressor |
| TW346397B (en) * | 1991-10-17 | 1998-12-01 | Univ California | Cell cycle controlling compositions and methods of using same |
| JPH08506001A (ja) * | 1992-10-01 | 1996-07-02 | ザ ゼネラル ホスピタル コーポレーション | 腫瘍サプレッサー遺伝子の機能検査 |
| JPH06296489A (ja) * | 1992-11-20 | 1994-10-25 | Univ Texas Syst | 網膜芽腫−関連タンパク質をコードする細胞性遺伝子 |
| US5496731A (en) * | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
| WO1995007708A2 (en) * | 1993-09-13 | 1995-03-23 | The Regents Of The University Of California | Therapeutic use of the retinoblastoma susceptibility gene product |
| US5550020A (en) * | 1994-07-08 | 1996-08-27 | Visible Genetics Inc. | Method, reagents and kit for diagnosis and targeted screening for retinoblastoma |
| US6974666B1 (en) * | 1994-10-21 | 2005-12-13 | Appymetric, Inc. | Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA |
| US5753439A (en) * | 1995-05-19 | 1998-05-19 | Trustees Of Boston University | Nucleic acid detection methods |
| US5670325A (en) * | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
| US5741650A (en) * | 1996-01-30 | 1998-04-21 | Exact Laboratories, Inc. | Methods for detecting colon cancer from stool samples |
| US5952178A (en) * | 1996-08-14 | 1999-09-14 | Exact Laboratories | Methods for disease diagnosis from stool samples |
| US6203993B1 (en) | 1996-08-14 | 2001-03-20 | Exact Science Corp. | Methods for the detection of nucleic acids |
| US6020137A (en) * | 1996-08-14 | 2000-02-01 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
| US6146828A (en) * | 1996-08-14 | 2000-11-14 | Exact Laboratories, Inc. | Methods for detecting differences in RNA expression levels and uses therefor |
| US6300077B1 (en) | 1996-08-14 | 2001-10-09 | Exact Sciences Corporation | Methods for the detection of nucleic acids |
| US5928870A (en) * | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
| US6100029A (en) * | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
| US5830665A (en) * | 1997-03-03 | 1998-11-03 | Exact Laboratories, Inc. | Contiguous genomic sequence scanning |
| US6406857B1 (en) | 1997-06-16 | 2002-06-18 | Exact Sciences Corporation | Methods for stool sample preparation |
| US6268136B1 (en) | 1997-06-16 | 2001-07-31 | Exact Science Corporation | Methods for stool sample preparation |
| US6280947B1 (en) | 1999-08-11 | 2001-08-28 | Exact Sciences Corporation | Methods for detecting nucleotide insertion or deletion using primer extension |
| US6503718B2 (en) | 1999-01-10 | 2003-01-07 | Exact Sciences Corporation | Methods for detecting mutations using primer extension for detecting disease |
| WO2000050640A1 (en) | 1999-02-25 | 2000-08-31 | Exact Laboratories, Inc. | Methods for preserving dna integrity |
| US6586177B1 (en) | 1999-09-08 | 2003-07-01 | Exact Sciences Corporation | Methods for disease detection |
| CA2394921A1 (en) | 1999-12-07 | 2001-06-14 | Anthony P. Shuber | Supracolonic aerodigestive neoplasm detection |
| US6428964B1 (en) | 2001-03-15 | 2002-08-06 | Exact Sciences Corporation | Method for alteration detection |
| WO2003071252A2 (en) | 2002-02-15 | 2003-08-28 | Exact Sciences Corporation | Methods for analysis of molecular events |
| US7981607B2 (en) | 2004-08-27 | 2011-07-19 | Esoterix Genetic Laboratories LLC | Method for detecting recombinant event |
| WO2006047787A2 (en) | 2004-10-27 | 2006-05-04 | Exact Sciences Corporation | Method for monitoring disease progression or recurrence |
| US9777314B2 (en) | 2005-04-21 | 2017-10-03 | Esoterix Genetic Laboratories, Llc | Analysis of heterogeneous nucleic acid samples |
| JP4928311B2 (ja) * | 2006-12-11 | 2012-05-09 | 本田技研工業株式会社 | 車両のドア及びその製造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4535058A (en) * | 1982-10-01 | 1985-08-13 | Massachusetts Institute Of Technology | Characterization of oncogenes and assays based thereon |
| US4599305A (en) * | 1984-07-16 | 1986-07-08 | The Regents Of The University Of California | Method and composition for detection of human chronic myelogenous leukemia |
| GB8712646D0 (en) * | 1987-05-29 | 1987-07-01 | Clayton Found Res | Structural evidence |
-
1987
- 1987-08-10 CA CA000544093A patent/CA1341576C/en not_active Expired - Fee Related
- 1987-08-11 AT AT94103625T patent/ATE230442T1/de not_active IP Right Cessation
- 1987-08-11 ES ES87307095T patent/ES2063739T3/es not_active Expired - Lifetime
- 1987-08-11 AT AT87307095T patent/ATE113993T1/de active
- 1987-08-11 DE DE3752360T patent/DE3752360T2/de not_active Expired - Lifetime
- 1987-08-11 DE DE3750738T patent/DE3750738T2/de not_active Expired - Lifetime
- 1987-08-11 AU AU76762/87A patent/AU600293B2/en not_active Expired
- 1987-08-11 JP JP62200755A patent/JP2779161B2/ja not_active Expired - Fee Related
- 1987-08-11 EP EP87307095A patent/EP0259031B1/de not_active Expired - Lifetime
- 1987-08-11 ES ES94103625T patent/ES2189795T3/es not_active Expired - Lifetime
- 1987-08-11 EP EP94103625A patent/EP0608004B1/de not_active Expired - Lifetime
-
1996
- 1996-08-05 JP JP8206165A patent/JP2902362B2/ja not_active Expired - Fee Related
-
1998
- 1998-03-02 JP JP10049626A patent/JP3051894B2/ja not_active Expired - Fee Related
- 1998-03-02 JP JP10049646A patent/JP3110372B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE3752360D1 (de) | 2003-02-06 |
| JP3051894B2 (ja) | 2000-06-12 |
| EP0608004A3 (en) | 1994-08-10 |
| EP0608004B1 (de) | 2003-01-02 |
| EP0608004A2 (de) | 1994-07-27 |
| EP0259031A3 (en) | 1990-09-12 |
| ES2063739T3 (es) | 1995-01-16 |
| JP3110372B2 (ja) | 2000-11-20 |
| AU600293B2 (en) | 1990-08-09 |
| JPH10337190A (ja) | 1998-12-22 |
| JPH10319013A (ja) | 1998-12-04 |
| JP2779161B2 (ja) | 1998-07-23 |
| ATE113993T1 (de) | 1994-11-15 |
| JP2902362B2 (ja) | 1999-06-07 |
| ATE230442T1 (de) | 2003-01-15 |
| DE3752360T2 (de) | 2004-02-12 |
| JPH09121898A (ja) | 1997-05-13 |
| EP0259031A2 (de) | 1988-03-09 |
| ES2189795T3 (es) | 2003-07-16 |
| JPS63119698A (ja) | 1988-05-24 |
| AU7676287A (en) | 1988-05-19 |
| DE3750738D1 (de) | 1994-12-15 |
| DE3750738T2 (de) | 1995-06-01 |
| EP0259031B1 (de) | 1994-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1341576C (en) | Diagnosis of retinoblastoma | |
| EP0390323B2 (de) | Nachweis des Ausfalls des Wildtyps des p53-Gens | |
| US6090566A (en) | Diagnostic method detecting loss of wild-type p53 | |
| US6800617B1 (en) | Methods for restoring wild-type p53 gene function | |
| AU699183B2 (en) | Laminin chains: diagnostic and therapeutic use | |
| US6677312B1 (en) | Methods for restoring wild-type p53 gene function | |
| EP0398955B1 (de) | Diagnose von retinoblastoma | |
| WO1992015602A1 (en) | Cancer diagnosis and therapy | |
| US5726018A (en) | Nucleic acid based assays to detect a novel mammalian protein associated with uncontrolled cell division | |
| WO1999001550A1 (en) | A method for detection of alterations in msh5 | |
| US6046009A (en) | Diagnosis and treatment of glaucoma | |
| US5731192A (en) | Collagen COL4A6: gene, protein and method of detecting collagen deficiency | |
| US5840491A (en) | DNA sequence encoding the Machado-Joseph disease gene and uses thereof | |
| US5578462A (en) | NF2 isoforms | |
| US6930175B1 (en) | Gene family with transformation modulating activity | |
| EP1045926B1 (de) | Eine familie von genen mit transformationsmodulierender aktivität | |
| US5830661A (en) | Diagnosis and treatment of glaucoma | |
| US20030162195A1 (en) | Prediction of cancer by detection of ATM mutations | |
| WO2001022864A9 (en) | Sequences characteristic of bladder cancer | |
| US20020098488A1 (en) | ATM mutations in breast cancer | |
| US20030186242A1 (en) | Human megakaryocyte-associated tyrosine kinase (MATK)-related gene variant associated with lung cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |
Effective date: 20140708 |